NEW YORK (360Dx) – HalioDx announced today it has inked five distribution deals covering 15 countries.
The agreements are with Hyupjin to cover South Korea; IDB Resources for Singapore , Malaysia, and Thailand; IPS Genomix for Lebanon, Jordan, Kingdom of Saudi Arabia, United Arab Emirates, Egypt, Oman, and Qata; MicroDiagnostics, covering Greece; and South Genetics, covering Argentina, Chile, and Uruguay.
The distributors will promote and sell HalioDx's Immunoscore assay. The new agreements complement four other similar deals reached this year, the Marseille, France-based immune-oncology firm said.
Immunoscore measures the density of two T lymphocyte populations to help physicians assess colon cancer prognosis. With the new agreements, the test is available in countries where it can inform treatment options for 56,000 new cases of stage II and II colon cancer, HalioDx CEO Vincent Fert said in a statement.
Stephane Debono, executive vice president of the diagnostics business unit of HalioDx, added the firm will "further expand this network in 2019 while supporting our new partners to advocate the introduction of Immunoscore in the routine practice of oncologists, initially in colon cancer but also in other solid tumor indications in which we are developing Immunoscore."
Financial and other terms of today's agreements were not disclosed.